Home
overview

What is this event about?

Imaging and cancer

The conference...

SMi is proud to present the 7th annual conference in its series on imaging for the purposes of developing novel cancer therapies.  Imaging in Cancer Drug Development 2011 will build on the success of the previous 6 years to bring your knowledge in this field in line with the latest developments.

Taking place in central London, UK, you will hear presentations from the key players in the cancer and imaging arena.  The conference will focus on a wide range of imaging techniques in a wide range of settings - from the preclinical, to the clinical, to the future of oncological imaging.  You will hear presentations from the leading experts in their fields on the latest developments in MRI, PET, SPECT, IR and more.

Attend this event to learn how best to use imaging techniques to expedite your oncology drug development process.

Keen to see the detailed programme?  Click here.

Want to download the brochure?  Click here.

Register for the event here!

Group discounts available - click here

 

Fancy speaking at the conference?  Do you know of anyone who may be interested in speaking?  We are always on the look-out for new speakers for our upcoming conferences.  Let us know - contact the Conference Producer.

For sponsorship and exhibitioning opportunities, contact our Sponsorship Department.

 Why should you attend this event?

What you will learn about

  • New techniques: the latest in new techniques and procedures for MRI, PET, SPECT and Mass Spectrometry
  • Clinical imaging with a focus on breast cancer
  • Preclinical imaging with a view to developing personalised cancer therapies
  • Future developments and improving the safety of imaging technologies
 Imaging in oncology

 

 Oncology imagin

How you will benefit

Hear from the leading experts in the imaging world

Focus on the best strategies to maximise the benefits of imaging in oncology drug development

Learn about future developments which will transform the use of imaging

Network with senior thought leaders working with imaging for drug development

Who should attend this event?

Chief Executives, Vice Presidents, Directors, Heads, Managers, Chief Scientists and Group Leaders of

  • Imaging
  • Medical Imaging
  • Cancer Drug Development
  • Oncology
  • Preclinical Oncology
  • Clinical Oncology
  • Research and Development
  • Clinical Technology
  • Specialised Therapeutics
  • Oncology Consultancy
  • Legislation and Policy Advice
  • Informatics 

Delegates at our previous imaging conferences came from across the world

Graph of delegates by region

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Helen Young

Helen Young, Principal Scientist, AstraZeneca

9:10 Assessing objective treatment response in oncology: RECIST and beyond

Helen Young

Helen Young, Principal Scientist, AstraZeneca

  • RECIST 1.1: new practice and implications in clinical studies
  • Role of central review and site review: regulatory & Pharma perspectives
  • Role of "real" time response monitoring: does the benefit outweigh the cost
  • Tumour volume: value adding or added complexity
  • 9:50 The role of PET in drug development

    Jan Passchier

    Jan Passchier, Director, PET and Radiochemistry, GlaxoSmithKline

  • What PET can do
  • Limitations
  • Future role
  • 10:30 Morning Coffee

    11:00 Monitoring reviewer metrics during independent central review (ICR)

    Karoline Meurer

    Karoline Meurer, , CoreLab Partners Europe GmbH

  • Two reader adjudication paradigm
  • Discordance rates
  • Individual reader metrics
  • Understanding and effective use of P chart analysis
  • 11:40 Preclinical SPECT/CT and PET/CT

    Lefteris Livieratos

    Lefteris Livieratos, Medical Physicist, Nuclear Medicine Department, Guy's and St Thomas' Hospitals

  • Novel methods with PET/CT and SPECT/CT for preclinical oncology development
  • Updates from the radiotracer development group
  • Real-life examples
  • Future directions
  • 12:20 Networking Lunch

    13:50 Pre-clinical, multi-modality imaging of tumour biology and response to treatment

    Simon Walker-Samuel

    Simon Walker-Samuel, Research Fellow, UCL Centre for Advanced Biomedical Imaging

    - Development of novel biomarkers of treatment response
    - New mechanisms of generating image contrast
    - Combining imaging modalities to increase specificity
    - Future directions

    14:30 Application of different imaging modalities in the drug development process

    Werner Scheuer

    Werner Scheuer, Group Leader, Preclinical Optical Imaging, Pharmacology TR-PD, Pharmaceutical Research, Roche Diagnostics

  • Utility of different modalities
  • Advantages and limitations from an industrial perspective
  • Future aspects
  • 15:10 Afternoon Tea

    15:40 Optical imaging agents and technologies used to study biologics and delivery vehicles in a tumour environment

    Rainer Kneuer

    Rainer Kneuer, Investigator III, Lab Head Tracer Development, Novartis Institutes for BioMdical Research

  • Biology Driven Customised Imaging Probe Design 
  • Optical molecular imaging "Toolbox" 
  • Synthesis and characterisation of optical imaging agents -general considerations 
  • Probes for imaging biologics - biologics as target specific ligands 
  • Probes for imaging guided drug delivery - nanoparticles to study tumour physiology 
  • Potential translation of optical imaging tools to the clinical arena
  • 16:20 Preclinical imaging applied to cancer biology and drug development studies

    William Gallagher

    William Gallagher, Vice Principal for Research and Innovation, UCD College of Life Sciences

  • Development of multi-modal small animal preclinical imaging facility
  • Use of optical and radionuclide approaches for molecular imaging
  • Application to cancer biology studies
  • Application to anti-cancer drug development studies
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Morning Chairman's Opening Remarks

    Rainer Kneuer

    Rainer Kneuer, Investigator III, Lab Head Tracer Development, Novartis Institutes for BioMdical Research

    9:10 Imaging of cancer and anti-cancer agents in vivo and ex vivo

    Geoff Boxer

    Geoff Boxer, Principal Research Associate (Oncology), Targeting & Imaging Group, UCL Cancer Institute

  • Developing models for translational studies to optimise dose scheduling and to demonstrate regional damage following therapy
  • Integrating quantitative microscopy with pre-clinical in vivo imaging 
  • Predicting and monitoring therapy by changes in the tumour micro-environment
  • Understanding the relationship of molecular markers of DNA-damage and repair to biodistribution of targeted therapeutics
  • Vascular development and treatment response over time using Photoacoustic Imaging (PAI), MRI and PET
  • Antibody pharmacodynamics (anti-vascular and tumour cell binding) using SPECT/CT 
  • Hypoxia imaging and therapy eg 64Cu ATSM and novel antibodies using PET and SPECT
  • Co-registration of different imaging modalities (in vivo and ex vivo)
  • Optimising single and combination strategies for clinical trials and personalised medicine
  • 10:00 Contrast-Enhanced Ultrasound (CEUS) Imaging Modality for the Evaluation of Angiogenesis Inhibitors Therapy

    Daniela Bokor

    Daniela Bokor, Medical Director Ultrasound, Bracco Imaging

  • CEUS can easily detect changes in tumour perfusion 
  • CEUS quantitative perfusion parameters predict tumour response to different treatments 
  • Final results of large French prospective study (19 centres, about 500 patients)
  • 10:50 Morning Coffee

    11:20 Biomarker investigation via stable isotope labelling and mass spectrometry of non-small lung cancer serum

    Gabriela Grigorean

    Gabriela Grigorean, Co-Ordinator, Mass Spectrometry Unit, European Institute Of Oncology

  • Perspective on efficacy of using serum depletion to remove most abundant proteins - will it hinder the finding of biomarkers?
  • Quantitative mass spectrometric data analysis - comments on obtaining valid results for potential lung cancer biomarkers
  • An up-to-date evaluation of how biomarker lists generated by various researchers compare
  • Advantages and problems of mass spectrometry in performing rapid, robust serum analyses as a supporting technique in oncological imaging
  • 12:05 Volumetric analysis of lesions in CT, MR and PET data

    Volker Dicken

    Volker Dicken, Lead Scientist, Oncological Imaging, Fraunhofer MEVIS

  • Novel image processing software increases sensitivity and reproducibility 2+ times in lesion size change determination
  • Similar effect in the reproducible definition of a PET metabolic volume
  • Challenges of consistently and efficiently handling multimodal data
  • 12:50 Networking Lunch

    14:30 Nexus Oncology

    Kath Clayton

    Kath Clayton, Clinical Operations Director, Nexus Oncology

  • Understanding the challenges of running imaging trials globally
  • Differing regulatory guidelines  - ensuring compliance
  • Standardisation of data collection and methods
  • 15:15 Existing and novel PET tracers for monitoring and predicting response to treatment

    Adriaan  Lammertsma

    Adriaan Lammertsma, Head, Dept Nud Med & Pet Research, Vu University Medical Center

  • Overview of current PET tracers - strengths and limitations
  • Challenges of developing and receiving regulatory approval for new PET tracers
  • Latest developments and examples of new tracers
  • 16:00 Chairman’s Closing Remarks

    16:10 Chairman's closing remarks and close of conference

    +

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.